Using CRISPR-Cas systems as antimicrobials

Current Opinion in Microbiology

Volumn 37, Issue , 2017, Pages 155-160

  Bikard, David ^a   Barrangou, Rodolphe ^b  

^a INSTITUT PASTEUR   (France)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CAS NUCLEASE; NUCLEASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL DNA; BIOLOGICAL PRODUCT;

BACTERIOPHAGE; CELL DEATH; CRISPR CAS SYSTEM; DNA DAMAGE; GENE TARGETING; NONHUMAN; PHAGEMID; REVIEW; BACTERIUM TRANSFORMATION; DNA CLEAVAGE; DRUG EFFECT; GENETIC ENGINEERING; METABOLISM; MICROBIAL VIABILITY; PLASMID;

ANTI-INFECTIVE AGENTS; BIOLOGICAL PRODUCTS; CRISPR-CAS SYSTEMS; DNA CLEAVAGE; DNA, BACTERIAL; GENETIC ENGINEERING; MICROBIAL VIABILITY; PLASMIDS; TRANSFORMATION, BACTERIAL;

EID: 85028725936     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2017.08.005     Document Type: Review

References (51)

1. Marraffini, L.A., CRISPR-Cas immunity in prokaryotes. Nature 526 (2015), 55–61.
2. Hsu, P.D., Lander, E.S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 157 (2014), 1262–1278.
3. Ledford, H., CRISPR, the disruptor. Nat News, 522, 2015, 20.
4. Pennisi, E., The CRISPR craze. Science 341 (2013), 833–836.
5. Makarova, K.S., Wolf, Y.I., Alkhnbashi, O.S., Costa, F., Shah, S.A., Saunders, S.J., Barrangou, R., Brouns, S.J.J., Charpentier, E., Haft, D.H., et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol 13 (2015), 722–736 This study updated the classification and nomenclature of CRISPR-Cas systems and outlined their occurrence and diversity in bacteria and archaea.
6. Brouns, S.J., Jore, M.M., Lundgren, M., Westra, E.R., Slijkhuis, R.J., Snijders, A.P., Dickman, M.J., Makarova, K.S., Koonin, E.V., van der Oost, J., Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321 (2008), 960–964.
7. Sinkunas, T., Gasiunas, G., Waghmare, S.P., Dickman, M.J., Barrangou, R., Horvath, P., Siksnys, V., In vitro reconstitution of Cascade-mediated CRISPR immunity in Streptococcus thermophilus. EMBO J 32 (2013), 385–394.
8. Garneau, J.E., Dupuis, M.E., Villion, M., Romero, D.A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadan, A.H., Moineau, S., The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468 (2010), 67–71.
9. Gasiunas, G., Barrangou, R., Horvath, P., Siksnys, V., Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci 109 (2012), 15539–15540.
10. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
11. Barrangou, R., Doudna, J.A., Applications of CRISPR technologies in research and beyond. Nat Biotechnol 34 (2016), 933–941.
12. Citorik, R.J., Mimee, M., Lu, T.K., Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32 (2014), 1141–1145 This report established a proof of concept that CRISPR-Cas9 systems can be delivered by phages to target E. coli in vitro and in vivo.
13. Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., Marraffini, L.A., Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res 41 (2013), 7429–7437.
14. Jiang, W., Bikard, D., Cox, D., Zhang, F., Marraffini, L.A., RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31 (2013), 233–239.
15. Luo, M.L., Mullis, A.S., Leenay, R.T., Beisel, C.L., Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression. Nucleic Acids Res 43 (2015), 674–681.
16. Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P., Lim, W.A., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152 (2013), 1173–1183.
17. Goren, M., Yosef, I., Qimron, U., Sensitizing pathogens to antibiotics using the CRISPR-Cas system. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 30 (2017), 1–6.
18. Horvath, P., Romero, D.A., Coute-Monvoisin, A.C., Richards, M., Deveau, H., Moineau, S., Boyaval, P., Fremaux, C., Barrangou, R., Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus. J Bacteriol 190 (2008), 1401–1412.
19. Stern, A., Keren, L., Wurtzel, O., Amitai, G., Sorek, R., Self-targeting by CRISPR: gene regulation or autoimmunity?. Trends Genet 26 (2010), 335–340.
20. Semenova, E., Jore, M.M., Datsenko, K.A., Semenova, A., Westra, E.R., Wanner, B., van der Oost, J., Brouns, S.J., Severinov, K., Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci U S A 108 (2011), 10098–10103.
21. Wiedenheft, B., van Duijn, E., Bultema, J.B., Waghmare, S.P., Zhou, K., Barendregt, A., Westphal, W., Heck, A.J., Boekema, E.J., Dickman, M.J., et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc Natl Acad Sci U S A 108 (2011), 10092–10097.
22. Sternberg, S.H., Redding, S., Jinek, M., Greene, E.C., Doudna, J.A., DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507 (2014), 62–67.
23. Paez-Espino, D., Morovic, W., Sun, C.L., Thomas, B.C., Ueda, K., Stahl, B., Barrangou, R., Banfield, J.F., Strong bias in the bacterial CRISPR elements that confer immunity to phage. Nat Commun, 4, 2013, 1430.
24. Datsenko, K.A., Pougach, K., Tikhonov, A., Wanner, B.L., Severinov, K., Semenova, E., Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system. Nat Commun, 3, 2012, 945.
25. Levy, A., Goren, M.G., Yosef, I., Auster, O., Manor, M., Amitai, G., Edgar, R., Qimron, U., Sorek, R., CRISPR adaptation biases explain preference for acquisition of foreign DNA. Nature 520 (2015), 505–510.
26. Modell, J.W., Jiang, W., Marraffini, L.A., CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Nature 544 (2017), 101–104.
27. Staals, R.H.J., Jackson, S.A., Biswas, A., Brouns, S.J.J., Brown, C.M., Fineran, P.C., Interference-driven spacer acquisition is dominant over naive and primed adaptation in a native CRISPR-Cas system. Nat Commun, 7, 2016, 12853.
28. Edgar, R., Qimron, U., The Escherichia coli CRISPR system protects from lambda lysogenization, lysogens, and prophage induction. J Bacteriol 192 (2010), 6291–6294 This is the first report of artificial self targeting by a CRISPR system.
29. Gomaa, A.A., Klumpe, H.E., Luo, M.L., Selle, K., Barrangou, R., Beisel, C.L., Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. MBio 5 (2013), e00928–e1013 This study showed that endogenous CRISPR-Cas systems can be repurposed to generate programmable cell death in bacteria and selectively target different genotypes in a mixed population.
30. Vercoe, R.B., Chang, J.T., Dy, R.L., Taylor, C., Gristwood, T., Clulow, J.S., Richter, C., Przybilski, R., Pitman, A.R., Fineran, P.C., Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands. PLoS Genet, 9, 2013, e1003454 This early report revealed the lethality and some genomic outcomes of self-targeting by CRISPR-Cas systems.
31. Westra, E.R., van Erp, P.B., Kunne, T., Wong, S.P., Staals, R.H., Seegers, C.L., Bollen, S., Jore, M.M., Semenova, E., Severinov, K., et al. CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3. Mol Cell 46 (2012), 595–605.
32. Caliando, B.J., Voigt, C.A., Targeted DNA degradation using a CRISPR device stably carried in the host genome. Nat Commun, 6, 2015, 6989.
33. Bikard, D., Hatoum-Aslan, A., Mucida, D., Marraffini, L.A., CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe 12 (2012), 177–186.
34. Beloglazova, N., Petit, P., Flick, R., Brown, G., Savchenko, A., Yakunin, A.F., Structure and activity of the Cas3 HD nuclease MJ0384, an effector enzyme of the CRISPR interference. EMBO J 30 (2011), 4616–4627.
35. Sinkunas, T., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., Siksnys, V., Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO J 30 (2011), 1335–1342.
36. Wigley, D.B., Bacterial DNA repair: recent insights into the mechanism of RecBCD, AddAB and AdnAB. Nat Rev Microbiol 11 (2013), 9–13.
37. Cui, L., Bikard, D., Consequences of Cas9 cleavage in the chromosome of Escherichia coli. Nucleic Acids Res 44 (2016), 4243–4251 This study investigated the outcomes of Cas9-based self-targeting in bacteria and established the interplay between DNA damage and DNA repair.
38. Hagens, S., Bläsi, U., Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 37 (2003), 318–323.
39. Moradpour, Z., Sepehrizadeh, Z., Rahbarizadeh, F., Ghasemian, A., Yazdi, M.T., Shahverdi, A.R., Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli. FEMS Microbiol Lett 296 (2009), 67–71.
40. Westwater, C., Kasman, L.M., Schofield, D.A., Werner, P.A., Dolan, J.W., Schmidt, M.G., Norris, J.S., Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47 (2003), 1301–1307.
41. Hagens, S., Habel, A., Ahsen, U. von, Gabain, A. von, Bläsi, U., Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48 (2004), 3817–3822.
42. Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., Fischetti, V.A., Marraffini, L.A., Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32 (2014), 1146–1150 This report established a proof of concept that CRISPR-Cas9 systems can be delivered by phages to target S. aureus in vitro and in vivo.
43. Yosef, I., Manor, M., Kiro, R., Qimron, U., Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci 112 (2015), 7267–7272 This study provides novel strategies to re-sensitize bacteria to antibiotics using plasmid targeting CRISPR-Cas systems.
44. Westra, E.R., Pul, Ü., Heidrich, N., Jore, M.M., Lundgren, M., Stratmann, T., Wurm, R., Raine, A., Mescher, M., Van Heereveld, L., et al. H-NS-mediated repression of CRISPR-based immunity in Escherichia coli K12 can be relieved by the transcription activator LeuO. Mol Microbiol 77 (2010), 1380–1393.
45. Labrie, S.J., Samson, J.E., Moineau, S., Bacteriophage resistance mechanisms. Nat Rev Microbiol 8 (2010), 317–327.
46. Sulakvelidze, A., Alavidze, Z., Morris, J.G., Bacteriophage therapy. Antimicrob Agents Chemother 45 (2001), 649–659.
47. Ando, H., Lemire, S., Pires, D.P., Lu, T.K., Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst 1 (2015), 187–196.
48. Mapes, A.C., Trautner, B.W., Liao, K.S., Ramig, R.F., Development of expanded host range phage active on biofilms of multi-drug resistant Pseudomonas aeruginosa. Bacteriophage, 6, 2016, e1096995.
49. Yosef, I., Goren, M.G., Globus, R., Molshanski-Mor, S., Qimron, U., Extending the host range of bacteriophage particles for DNA transduction. Mol Cell, 66, 2017 721–728.e3.
50. Selle, K., Klaenhammer, T.R., Barrangou, R., CRISPR-based screening of genomic island excision events in bacteria. Proc Natl Acad Sci 112 (2015), 8076–8081 This report established that native CRISPR-Cas systems can be co-opted to select for rare deletion events of expendable genetic islands.
51. Pawluk, A., Staals, R.H.J., Taylor, C., Watson, B.N.J., Saha, S., Fineran, P.C., Maxwell, K.L., Davidson, A.R., Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. Nat Microbiol, 1, 2016, 16085.